In a discussion of COVID-19 treatment options for MCAS and mastocytosis, Valent et al. [57] observe that “anti–mediator-type drugs, including antihistamines, antileukotrienes, cromones, and omalizumab (anti-IgE), have been in use for many years, and there is no reasonable evidence to suggest that these drugs exert immunosuppressive effects, even when used over several years.” Hafezi et al. [65] suggest a range of potential drugs for treating COVID-19 cytokine storm including mast cell stabilizing drugs, tryptase inhibitors, zinc-mediated inhibitors, and tryptase-specific antibodies. The gene discussed is IGHE; the disease is mastocytosis.